Pacer Advisors
IGMS

Pacer Advisors’s IGM Biosciences IGMS Stock Holding History

Pacer Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-890
Closed -$68K – 1472
2021
Q1 		$68K Buy
890
+6
+0.7% +$546 ﹤0.01% 1388
2020
Q4 		$78K Buy
884
+529
+149% +$37.2K ﹤0.01% 1384
2020
Q3 		$26K Buy
+355
New +$21K ﹤0.01% 1346

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pacer Advisors's IGMS Position: Q2 2021 in Review

Pacer Advisors sold out of IGM Biosciences (IGMS) in Q2 2021, closing a stake of 890 shares — an estimated $68K sold.

Pacer Advisors first reported a position in IGMS in Q3 2020 and held it in 3 quarters. The position peaked at $78K in Q4 2020. 104 funds tracked by Wall St. Rank hold IGMS as of Q2 2021.

  • Pacer Advisors reported no remaining IGM Biosciences position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 890 IGM Biosciences shares in Q2 2021, an estimated $68K.
  • Pacer Advisors first reported a position in IGM Biosciences in Q3 2020 and held it in 3 quarters.
  • Pacer Advisors's IGM Biosciences position peaked at $78K in Q4 2020.
  • 104 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.